Exome Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Exome Asset Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-92,055	Closed	-$1.04M	–	63
2025 Q4	$1.04M	Sell	92,055 -6,744	-7%	-$68.6K	0.5%	52
2025 Q3	$909K	Sell	98,799 -346,150	-78%	-$2.5M	0.55%	54
2025 Q2	$3.06M	Sell	444,949 -244,188	-35%	-$1.31M	2.28%	17
2025 Q1	$1.98M	Buy	689,137 +405,538	+143%	+$1.49M	1.76%	27
2024 Q4	$1.33M	Buy	+283,599	New	+$1.05M	1%	37
2024 Q3	–	Sell	-302,700	Closed	-$1.88M	–	70
2024 Q2	$1.88M	Buy	+302,700	New	+$2.29M	1.67%	29

Other funds holding FULC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $935M AUM 298.58% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Exome Asset Management's FULC Position: Q1 2026 in Review

Exome Asset Management sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 92,055 shares — an estimated $1.04M sold.

Exome Asset Management first reported a position in FULC in Q2 2024 and held it in 6 quarters. The position peaked at $3.06M in Q2 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Exome Asset Management reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
Exome Asset Management sold 92,055 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.04M.
Exome Asset Management first reported a position in Fulcrum Therapeutics in Q2 2024 and held it in 6 quarters.
Exome Asset Management's Fulcrum Therapeutics position peaked at $3.06M in Q2 2025.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.